No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NVCR240517C15000
- 1.46
- +0.26+21.67%
15min DelayClose May 10 16:00 ET
1.50High1.30Low
1.30Open1.20Pre Close138 Volume1.02K Open Interest15.00Strike Price18.72KTurnover0.00%IV-0.27%PremiumMay 17, 2024Expiry Date1.47Intrinsic Value100Multiplier6DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma11.56Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Unveiling 8 Analyst Insights On NovoCure
Throughout the last three months, 8 analysts have evaluated NovoCure (NASDAQ:NVCR), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings, shed
Earnings Call Summary | Novocure(NVCR.US) Q1 2024 Earnings Conference
The following is a summary of the NovoCure Limited (NVCR) Q1 2024 Earnings Call Transcript:Financial Performance:NovoCure reported a net revenue of $139 million in Q1 2024, up 13% year-over-year. The
Novocure Is Maintained at Neutral by HC Wainwright & Co.
Novocure Is Maintained at Neutral by HC Wainwright & Co.
NovoCure Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 70.54% HC Wainwright & Co. $24 → $22 Maintains Neutral 04/10/2024 117.05% Piper Sandler $25 → $
Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and NovoCure (NVCR)
Express News | Novocure Limited : H.c. Wainwright Cuts Target Price to $22 From $24
Comments
$Novocure(NVCR.US$ pt anyone?
2
$Novocure(NVCR.US$ I placed limit buy @13.1 but got filled at 13.299, I noticed this many times in this app, they are causing slippage, anyone noticed same?
$iBio Inc (IBIO.US)$ IBIO: 119% | IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for obesity and cardiometabolic diseases.
DRCT: -49% | Direct Digital Holdings shares are trading lower after the company reported worse-than-expected Q4 financial results.
NVCR: 42% | Novocure shares are trading higher after the company's METIS Phase 3 trial met primary endpoint, demonstrating statistically significant extension in time to intracranial ...
DRCT: -49% | Direct Digital Holdings shares are trading lower after the company reported worse-than-expected Q4 financial results.
NVCR: 42% | Novocure shares are trading higher after the company's METIS Phase 3 trial met primary endpoint, demonstrating statistically significant extension in time to intracranial ...
Morning Movers
Gapping up
$Deutsche Bank(DB.US$ shares rose 3% after Morgan Stanley upgraded the stock to overweight, suggesting further potential growth following a strong performance in 2024.
$Merck & Co(MRK.US$ stock rose 4.8% after its drug for treating a rare lung disease received FDA approval.
$Trump Media & Technology(DJT.US$ stock jumped 14%, following gains after its Nasdaq debut.
$Robinhood(HOOD.US$ stock climbed 6...
Gapping up
$Deutsche Bank(DB.US$ shares rose 3% after Morgan Stanley upgraded the stock to overweight, suggesting further potential growth following a strong performance in 2024.
$Merck & Co(MRK.US$ stock rose 4.8% after its drug for treating a rare lung disease received FDA approval.
$Trump Media & Technology(DJT.US$ stock jumped 14%, following gains after its Nasdaq debut.
$Robinhood(HOOD.US$ stock climbed 6...
32
Key Takeaway
GameStop ( $GameStop(GME.US$ ) and Forge Global ( $Forge Global(FRGE.US$ ) face pre-market declines of 17% and 11% respectively, while Novocure ( $Novocure(NVCR.US$ ) surges 30% on positive trial results.
Merck ( $Merck & Co(MRK.US$ ) gains 4% after FDA approval of its treatment, highlighting a day of significant volatility and strategic moves in the U.S. stock market.
A Glimpse into Quarter-End Moves
As the curtains draw near on...
GameStop ( $GameStop(GME.US$ ) and Forge Global ( $Forge Global(FRGE.US$ ) face pre-market declines of 17% and 11% respectively, while Novocure ( $Novocure(NVCR.US$ ) surges 30% on positive trial results.
Merck ( $Merck & Co(MRK.US$ ) gains 4% after FDA approval of its treatment, highlighting a day of significant volatility and strategic moves in the U.S. stock market.
A Glimpse into Quarter-End Moves
As the curtains draw near on...
1
Read more
灵巧的托拜厄斯 : 有
Kenneil NugentOP : lol no help